In this episode, Dr. Mohamad Toutounji explores how AI is reshaping drug discovery across small molecules, biologics, ADCs, and nucleic acid-based therapies. We break down the real value of AI in target identification, molecule design, predictive modeling, preclinical optimization, and clinical trial simulation—backed by real-world examples from leaders like Insilico, Recursion, and Genentech. We also cover common misconceptions and practical limitations of AI in pharma.
 If you're a biotech executive, scientist, investor, or innovation leader—this episode is for you.